CDC Logo Tuberculosis Information CD-ROM   Image of people
jump over main navigation bar to content area
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Ordering Information


U.S. Department of Health and Human Services


TB Guidelines


Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - MMWR 2003; 52 (No. 31)

Treatment of Tuberculosis - MMWR 2003; 52 (No. RR-11)

» Errata: Treatment of Tuberculosis - MMWR 2005; 52 (RR-11)

Guidelines for Environmental Infection Control in Health-Care Facilities - MMWR 2003; 52 (No. RR-10)
Timing of Tuberculosis Screening and Smallpox Vaccination - Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program - MMWR 2003; 52 (No. RR-7)

Archived TB Guidelines

The documents listed below are historical, archived information. The information contained in these documents, while accurate at the time of release, may not be the most current available.

Guidelines for Using the QuantiFERON®-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection - MMWR 2003; 52 (RR-2); 15-18



Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination -

Please send comments/suggestions/requests to:, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333